Finney Rutten Lila J, Jacobson Robert M, Wilson Patrick M, Jacobson Debra J, Fan Chun, Kisiel John B, Sweetser Seth, Tulledge-Scheitel Sidna M, St Sauver Jennifer L
Population Health Science Program, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
Population Health Science Program, Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Mayo Clinic, Rochester, MN; Division of Community Pediatric and Adolescent Medicine, Department of Pediatric and Adolescent Medicine, Mayo Clinic, Rochester, MN.
Mayo Clin Proc. 2017 May;92(5):726-733. doi: 10.1016/j.mayocp.2017.01.019.
To characterize early adoption of a novel multitarget stool DNA (MT-sDNA) screening test for colorectal cancer (CRC) screening and to test the hypothesis that adoption differs by demographic characteristics and prior CRC screening behavior and proceeds predictably over time.
We used the Rochester Epidemiology Project research infrastructure to assess the use of the MT-sDNA screening test in adults aged 50 to 75 years living in Olmsted County, Minnesota, in 2014 and identified 27,147 individuals eligible or due for screening colonoscopy from November 1, 2014, through November 30, 2015. We used electronic Current Procedure Terminology and Health Care Common Procedure codes to evaluate early adoption of the MT-sDNA screening test in this population and to test whether early adoption varies by age, sex, race, and prior CRC screening behavior.
Overall, 2193 (8.1%) and 974 (3.6%) individuals were screened by colonoscopy and MT-sDNA, respectively. Age, sex, race, and prior CRC screening behavior were significantly and independently associated with MT-sDNA screening use compared with colonoscopy use after adjustment for all other variables (P<.05 for all). The rates of adoption of MT-sDNA screening increased over time and were highest in those aged 50 to 54 years, women, whites, and those who had a history of screening. The use of the MT-sDNA screening test varied predictably by insurance coverage. The rates of colonoscopy decreased over time, whereas overall CRC screening rates remained steady.
The results of the present study are generally consistent with predictions derived from prior research and the diffusion of innovation framework, pointing to increasing use of the new screening test over time and early adoption by younger patients, women, whites, and those with prior CRC screening.
描述一种用于结直肠癌(CRC)筛查的新型多靶点粪便DNA(MT-sDNA)筛查试验的早期采用情况,并检验以下假设:采用情况因人口统计学特征和既往CRC筛查行为而异,且随时间推移具有可预测性。
我们利用罗切斯特流行病学项目的研究基础设施,评估了2014年居住在明尼苏达州奥尔姆斯特德县的50至75岁成年人中MT-sDNA筛查试验的使用情况,并确定了2014年11月1日至2015年11月30日期间符合条件或应接受结肠镜筛查的27147名个体。我们使用电子当前操作术语和医疗保健通用程序编码来评估该人群中MT-sDNA筛查试验的早期采用情况,并检验早期采用是否因年龄、性别、种族和既往CRC筛查行为而有所不同。
总体而言,分别有2193名(8.1%)和974名(3.6%)个体接受了结肠镜检查和MT-sDNA筛查。在对所有其他变量进行调整后,与结肠镜检查相比,年龄、性别、种族和既往CRC筛查行为与MT-sDNA筛查的使用显著且独立相关(所有P<0.05)。MT-sDNA筛查的采用率随时间增加,在50至54岁的人群、女性、白人以及有筛查史的人群中最高。MT-sDNA筛查试验的使用因保险覆盖情况而异,具有可预测性。结肠镜检查的比率随时间下降,而总体CRC筛查率保持稳定。
本研究结果总体上与先前研究和创新扩散框架得出的预测一致,表明随着时间推移,新筛查试验的使用增加,年轻患者、女性、白人以及有既往CRC筛查史的患者早期采用该试验。